评估 EYU688 对登革热患者的疗效、安全性和药代动力学的研究
一项随机、参与者和研究人员盲法、安慰剂对照、平行组研究,旨在评估 EYU688 对登革热患者的疗效、安全性和药代动力学
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
研究概览
详细说明
This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever.
Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK [cohort 1] and sparse PK sampling [cohort 2]).
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Novartis Pharmaceuticals
- 电话号码:+41613241111
- 邮箱:novartis.email@novartis.com
研究联系人备份
- 姓名:Novartis Pharmaceuticals
学习地点
-
-
Karnataka
-
Belagavi、Karnataka、印度、590010
- 招聘中
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai、Maharashtra、印度、400008
- 撤销
- Novartis Investigative Site
-
Pune、Maharashtra、印度、411013
- 招聘中
- Novartis Investigative Site
-
-
Rajasthan
-
Jaipur、Rajasthan、印度、302017
- 招聘中
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai、Tamil Nadu、印度、600113
- 招聘中
- Novartis Investigative Site
-
-
-
-
Atlántico
-
Barranquilla、Atlántico、哥伦比亚、080012
- 招聘中
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga、Santander Department、哥伦比亚、681017
- 招聘中
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali、Valle del Cauca Department、哥伦比亚、760032
- 招聘中
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City、墨西哥、68020
- 招聘中
- Novartis Investigative Site
-
Veracruz、墨西哥、91855
- 招聘中
- Novartis Investigative Site
-
-
-
-
Amazonas
-
Manaus、Amazonas、巴西、69040-000
- 招聘中
- Novartis Investigative Site
-
-
Federal District
-
Brasília、Federal District、巴西、71635-580
- 招聘中
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90560-032
- 招聘中
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、巴西、21040-360
- 招聘中
- Novartis Investigative Site
-
-
São Paulo
-
Sorocaba、São Paulo、巴西、18040-425
- 招聘中
- Novartis Investigative Site
-
São Caetano do Sul、São Paulo、巴西、09521-160
- 招聘中
- Novartis Investigative Site
-
São José do Rio Preto、São Paulo、巴西、15090 000
- 招聘中
- Novartis Investigative Site
-
-
-
-
-
Singapore、新加坡、169608
- 招聘中
- Novartis Investigative Site
-
-
Singapore
-
Singapore、Singapore、新加坡、308433
- 招聘中
- Novartis Investigative Site
-
-
-
-
-
Haiphong、越南、180000
- 招聘中
- Novartis Investigative Site
-
Hanoi、越南、100000
- 招聘中
- Novartis Investigative Site
-
Ho Chi Minh City、越南、700000
- 招聘中
- Novartis Investigative Site
-
-
-
-
-
Kuala Selangor、马来西亚、68000
- 招聘中
- Novartis Investigative Site
-
-
Pahang
-
Kuantan、Pahang、马来西亚、25200
- 招聘中
- Novartis Investigative Site
-
-
Perak
-
Ipoh、Perak、马来西亚、30450
- 招聘中
- Novartis Investigative Site
-
-
Pulau Pinang
-
Seberang Jaya、Pulau Pinang、马来西亚、13700
- 招聘中
- Novartis Investigative Site
-
-
Sarawak
-
Miri、Sarawak、马来西亚、98000
- 招聘中
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
- Nausea or vomiting.
- Presence of rash, aches or pains including headache, muscle or joint pain.
- Onset of fever ≤ 48 hours prior to treatment start.
- Positive test on dengue fever.
Exclusion Criteria:
-
Participants with any of abnormalities of clinical laboratory parameters.
-
Usage of any anticoagulant drugs.
-
Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
-
Pregnant or nursing (lactating) women.
-
Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
-
Participants with any of the following abnormalities of clinical laboratory parameters at screening:
- Hemoglobin <12.0 g/dL in males; <11.0 g/dL in females
- Hematocrit >52 % in males; >46 % in females
- Absolute neutrophil count <1500/μL
- Platelet count <80,000/mm3
- Creatinine >165 μmol/L in males; >130 μmol/L in females
- Serum creatine kinase > 600 U/L
- ALT, AST levels more than 3 X upper limit of normal (ULN)
- Total bilirubin >24 μmol/L
-
Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
-
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
-
History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:
- QTcF > 450 msec (males)
- QTcF > 460 msec (females)
Other protocol-defined inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Matching placebo |
Matching placebo administered orally as capsules |
|
实验性的:EYU688
EYU688 administered by oral route |
EYU688 administered by oral route |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
大体时间:From predose to 48 hours post treatment start
|
Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline. |
From predose to 48 hours post treatment start
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
大体时间:From fever onset to Day 15
|
Efficacy assessment of EYU688. It will allow to assess the time needed between fever onset and defervescence. |
From fever onset to Day 15
|
|
Time from fever onset to the first of two consecutive negative viremia by PCR
大体时间:From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From fever onset to Day 15
|
|
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
大体时间:From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day 15 |
From fever onset to Day 15
|
|
Changes of viral load over time
大体时间:From baseline to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From baseline to Day 15
|
|
Incidence and severity of Adverse Events (AEs)
大体时间:From inclusion to Day 15
|
Incidence and severity of AEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
From inclusion to Day 15
|
|
Incidence and severity of Serious Adverse Events (SAEs)
大体时间:From inclusion to Day 35
|
Incidence and severity of SAEs by treatment group |
From inclusion to Day 35
|
|
Change of white blood cell count over time from baseline
大体时间:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of platelet count over time
大体时间:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of hematocrit level and percentage increase from baseline over time
大体时间:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of AST, ALT levels over time
大体时间:From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
No warning signs by day 7 of fever onset
大体时间:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of severe dengue fever
大体时间:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of dengue hemorrhagic fever (DHF)
大体时间:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Plasma leakage
大体时间:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Requiring fluid infusion
大体时间:From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Time from fever onset to clinical recovery
大体时间:From fever onset to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From fever onset to Day 15
|
|
PK parameter (Cmax)
大体时间:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (Tmax)
大体时间:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (partial AUCs)
大体时间:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK concentrations following multiple doses
大体时间:From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CEYU688A12201
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.